<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Sol-gel Technologies Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/sol-gel-technologies-ltd</link>
    <description>Latest news and press releases for Sol-gel Technologies Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 28 May 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/sol-gel-technologies-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c06778dffbe2df1187a4.webp</url>
      <title>Sol-gel Technologies Ltd.</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd</link>
    </image>
    <item>
      <title>Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-first-quarter-2026-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-first-quarter-2026-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 GMT</pubDate>
      <description>Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investorsPivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026Sol-Gel s</description>
    </item>
    <item>
      <title>Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-technologies-ltd-announces-pricing-of-oversubscribed-underwritten-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-technologies-ltd-announces-pricing-of-oversubscribed-underwritten-offering</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten</description>
    </item>
    <item>
      <title>Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-files-annual-report-on-form-20-f-for-the-year-ended-december-31-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-files-annual-report-on-form-20-f-for-the-year-ended-december-31-2025</guid>
      <pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form</description>
    </item>
    <item>
      <title>Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-provides-following-unblinding-120000499</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-provides-following-unblinding-120000499</guid>
      <pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding, the data from the vehicle-controlled Phase 1b proof-of-concept study did not show differentiation between SGT-210 and vehicle on</description>
    </item>
    <item>
      <title>Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-third-quarter-123000367</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-third-quarter-123000367</guid>
      <pubDate>Thu, 20 Nov 2025 12:30:00 GMT</pubDate>
      <description>Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t</description>
    </item>
    <item>
      <title>Sol-Gel Announces Health Canada Approval of EPSOLAY®</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-health-canada-110000441</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-health-canada-110000441</guid>
      <pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlotinib ointment, 5%) on Darier disease patients and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced today that on August 27, 2025 Hea</description>
    </item>
    <item>
      <title>Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-second-quarter-110000749</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-second-quarter-110000749</guid>
      <pubDate>Fri, 15 Aug 2025 11:00:00 GMT</pubDate>
      <description>Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoingSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025Following recent transactions, Sol-Gel’s cash runway is expected to extend into the first quarter of 20</description>
    </item>
    <item>
      <title>Sol-Gel Reports First Quarter 2025 Results</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-first-quarter-111500229</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-first-quarter-111500229</guid>
      <pubDate>Fri, 23 May 2025 11:15:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. Th</description>
    </item>
    <item>
      <title>Sol-Gel Announces Reverse Share Split</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-reverse-share-110000739</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-reverse-share-110000739</guid>
      <pubDate>Thu, 01 May 2025 11:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders’ approval for the Reverse Spli</description>
    </item>
    <item>
      <title>Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-mayne-pharma-announce-124000896</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-mayne-pharma-announce-124000896</guid>
      <pubDate>Thu, 17 Apr 2025 12:40:00 GMT</pubDate>
      <description>Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210</description>
    </item>
    <item>
      <title>Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/appointment-of-dr-bryan-jones-as-an-advisor-to-lead-sol-gel-special-projects</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/appointment-of-dr-bryan-jones-as-an-advisor-to-lead-sol-gel-special-projects</guid>
      <pubDate>Tue, 04 Feb 2025 05:00:00 GMT</pubDate>
      <description>Vancouver, British Columbia--(Newsfile Corp. - February 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the &quot;Company&quot; or</description>
    </item>
    <item>
      <title>Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-requirement</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-requirement</guid>
      <pubDate>Wed, 20 Nov 2024 05:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients</description>
    </item>
    <item>
      <title>Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Fri, 15 Nov 2024 05:00:00 GMT</pubDate>
      <description>Mori Arkin&apos;s appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with</description>
    </item>
    <item>
      <title>Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-second-quarter-2024-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-second-quarter-2024-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Fri, 16 Aug 2024 04:00:00 GMT</pubDate>
      <description>Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical</description>
    </item>
    <item>
      <title>Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-the-signing-of-six-exclusive-license-agreements-to-commercialize-twyneor-and-epsolayr-in-europe-and-south-africa</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-the-signing-of-six-exclusive-license-agreements-to-commercialize-twyneor-and-epsolayr-in-europe-and-south-africa</guid>
      <pubDate>Thu, 25 Jul 2024 04:00:00 GMT</pubDate>
      <description>Sol-Gel to receive upfront and regulatory milestone payments totaling in up to low 7-digit USD and either fixed transfer sale price or low double-digit</description>
    </item>
    <item>
      <title>Sol-Gel Technologies Announces Management Realignment</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-technologies-announces-management-realignment</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-technologies-announces-management-realignment</guid>
      <pubDate>Mon, 15 Jul 2024 04:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients</description>
    </item>
    <item>
      <title>Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-receipt-of-nasdaq-minimum-price-notice</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-announces-receipt-of-nasdaq-minimum-price-notice</guid>
      <pubDate>Tue, 28 May 2024 04:00:00 GMT</pubDate>
      <description>NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with</description>
    </item>
    <item>
      <title>Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-first-quarter-2024-financial-results-and-provides-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-reports-first-quarter-2024-financial-results-and-provides-corporate-updates</guid>
      <pubDate>Mon, 20 May 2024 04:00:00 GMT</pubDate>
      <description>Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase</description>
    </item>
    <item>
      <title>Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-and-beimei-pharma-announce-an-asset-purchase-agreement-to-commercialize-twyneor-in-the-mainland-of-china-hong-kong-macau-taiwan-and-israel</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gel-and-beimei-pharma-announce-an-asset-purchase-agreement-to-commercialize-twyneor-in-the-mainland-of-china-hong-kong-macau-taiwan-and-israel</guid>
      <pubDate>Thu, 16 May 2024 04:00:00 GMT</pubDate>
      <description>Sol-Gel to receive a total consideration of up to US$15 million, out of which US$10 million will be paid as upfront and regulatory milestones NESS ZIONA,</description>
    </item>
    <item>
      <title>Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream</title>
      <link>https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gels-collaboration-partner-first-to-file-anda-drug-product-generic-to-zoryver-cream</link>
      <guid isPermaLink="true">https://6ix.com/company/sol-gel-technologies-ltd/news/sol-gels-collaboration-partner-first-to-file-anda-drug-product-generic-to-zoryver-cream</guid>
      <pubDate>Mon, 01 Apr 2024 04:00:00 GMT</pubDate>
      <description>Patent challenge initiated by Arcutis Biotherapeutics NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a</description>
    </item>
  </channel>
</rss>